Jazz Presents New Xywav Data at SLEEP 2026 Meeting
DUBLIN, Ireland, June 16, 2026 Jazz Pharmaceuticals plc has unveiled extensive late-breaking research at SLEEP 2026, presenting 11 new...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
DUBLIN, Ireland, June 16, 2026 Jazz Pharmaceuticals plc has unveiled extensive late-breaking research at SLEEP 2026, presenting 11 new...
DUBLIN, Ireland, June 4, 2026 Jazz Pharmaceuticals has announced the presentation of an extensive portfolio of new clinical and...
DUBLIN, Ireland, April 9, 2026 Jazz Pharmaceuticals plc has announced the presentation of six scientific abstracts, including one oral...
